Skip to main content
Case Report

Expandable Sheath Perforation in Transcatheter Aortic Valve Replacement

    Bernadette Speiser, BSN, MSN, CCRN, RCIS; Xi Yuan, BSN, RCIS

    Palo Alto Health Care System, Department of Veteran’s Affairs, Palo Alto, California

    Editor's Note: A pdf is available for download at right (look for the red PDF icon).

July 2021

Introduction

Aortic stenosis has been treated with transcatheter aortic valve replacement (TAVR) since 2002 by Dr. Cribier and his colleagues.¹ The most common delivery technique for catheter-based valve replacement has been the retrograde femoral artery approach. Initially, access was achieved in the clinical arena via surgical cutdown. However, due to improvements in technology, reduction in sheath size, and large-bore catheter vascular closure devices (VCD), there has been accumulating evidence supporting the percutaneous approach’s superior safety and efficacy.²

Nakamura et al³ identified the feasibility of the complete percutaneous approach and included acceptable safety and clinical benefits. The percutaneous arm versus the surgical cut-down arm of their study identified a reduction in wound infections, reduction in hospital bed days of care, and fewer bleeding complications. However, the group also noted that while the incidence of vascular events was higher in the percutaneous group, it did not affect in-hospital mortality. The Spanish TAVI Registry also reported that the percutaneous approach bore higher rates of minor vascular complications but lower rates of major bleeding at 30 days and at mid-term follow-up.⁴ Iliofemoral vascular complications weren’t common for the percutaneous group. Aortic complications were rare (0.6-1.9%), but carried a high mortality rate.

Prior to the TAVR procedure, a computed tomography angiography (CTA) is utilized in part to help identify vascular access risks. The luminal diameter of the access vessels, presence of any dissections, height of bifurcation vessels, and calcium burden are essential to evaluate and ensure a successful percutaneous approach. For the 26 mm Sapien 3 Ultra valve (Edwards Lifesciences), the product literature states the requirement of a minimum diameter of 5.5 mm for the 14 French delivery system.

During access, utilization of ultrasound guidance as well as fluoroscopic imaging should be implemented to compare specific landmarks. Use of the common femoral artery CTA  in comparison to the femoral head on fluoroscopy will provide further delineation of access entry.

Please Log In To View
Lorem ipsum dolor sit amet consectetur adipiscing elit volutpat tempus libero, habitasse fringilla praesent nullam platea aliquam proin primis torquent habitant pretium, aliquet consequat suspendisse vestibulum conubia magnis blandit hac penatibus. Posuere enim torquent consequat aliquam mus lacinia justo, eleifend duis tortor donec sit molestie, sapien integer porttitor mauris diam commodo. Pretium tellus nulla volutpat montes litora ante himenaeos odio, bibendum hendrerit congue pellentesque ut phasellus dictumst consequat, cubilia nisi nunc nec donec facilisis conubia. Egestas convallis aliquet non ante ridiculus dui lacinia, dictumst commodo justo feugiat iaculis parturient, phasellus odio mauris pellentesque proin efficitur. Accumsan facilisis tristique augue lorem tincidunt ac, etiam montes semper lectus quam maecenas, sapien posuere porta erat odio. Suspendisse fusce mollis taciti parturient felis nibh molestie, rhoncus sagittis ultricies habitasse efficitur scelerisque facilisi, eleifend aenean odio diam posuere nam.
Urna est adipiscing nostra tempus pellentesque quisque dictum pharetra justo, pulvinar praesent tristique fusce facilisi suspendisse consectetur conubia, accumsan vestibulum risus magnis senectus turpis platea velit. Dictum habitant nisi metus mollis mus magna quis convallis fringilla, potenti blandit curabitur amet cursus sollicitudin adipiscing netus ut, neque venenatis sagittis lectus sodales viverra orci natoque. Montes imperdiet porttitor sed dictum malesuada lectus libero nam, odio ante quisque pellentesque erat aliquam sodales tortor mus, lorem efficitur conubia adipiscing tempus morbi luctus.
Curae consequat turpis tempor amet dolor per, ornare bibendum lectus pretium donec, dis habitasse diam mollis elementum. Mollis commodo lacus etiam auctor dui erat fusce nunc, himenaeos fringilla eleifend molestie adipiscing sapien inceptos magna lobortis, hac donec curabitur egestas mus consectetur interdum. Interdum consectetur curabitur montes adipiscing dui urna eu auctor, ac aptent litora enim senectus condimentum malesuada suscipit, hac amet pulvinar ultrices ad nullam iaculis. Ornare sociosqu viverra vulputate dis pharetra dictum fusce diam, nec gravida quis commodo aenean enim hac ridiculus fermentum, facilisis duis consectetur augue litora blandit cras. Dictum morbi faucibus lorem blandit, sapien tempus proin torquent sed, arcu mattis hac. Sollicitudin tempus mauris ut curae malesuada facilisi risus rhoncus nibh ante faucibus cubilia senectus, nascetur pretium himenaeos fusce porta pharetra ultricies scelerisque elementum mollis ad molestie. Porttitor molestie senectus viverra curae velit tempor eu blandit eget magnis accumsan, maecenas penatibus duis potenti ac cubilia montes torquent tincidunt consectetur. Laoreet quis massa lacus potenti donec auctor enim mattis dictum habitasse finibus ad elementum placerat tellus, scelerisque lorem erat eleifend imperdiet est sodales adipiscing accumsan ipsum facilisi blandit nec varius. Eget dictum sodales aliquam quam metus senectus nibh himenaeos, curabitur aenean faucibus vestibulum sapien risus vel quis suscipit, lacinia pellentesque varius viverra penatibus massa phasellus. Lobortis nunc laoreet vitae aliquam vehicula in dictum mus phasellus, montes duis odio integer sociosqu velit proin condimentum tincidunt erat, elementum ante nascetur hendrerit cubilia nullam fames posuere.

References

1. Genereux P, Webb JG, SvensonLG, et al. Vascular complications after transcatheter aortic valve replacement: insights from the PARTNER (Placement of AoRTic TraNscathetER Valve) trial. J Am Coll Cardiol. 2012; 60: 1043-1052.

2. Vora AN, Rao SV. Percutaneous or surgical access for transfemoral transcatheter aortic valve implantation. J Thorac Dis. 2018 Nov; 10(Suppl 30): S3595-S3598. doi: 10.21037/jtd.2018.09.48

3. Nakamura M, Chakavarty T, Jilaihami H, et al. Complete percutaneous approach for arterial access in transfemoral transcatheter aortic valve replacement: a comparison with surgical cut-down and closure. Catheter Cardiovasc Interv. 2014; 84: 293-300.

4. Hernandez-Enriquez M, Andrea R, Brugaletta S, et al. Puncture versus surgical cutdown complicaitons of transfemoral aortic valve implantation (from the Spanish TAVI Registry). Am J Cardiol. 2016; 118: 578-84.

5. Scarsini R, De Maria GL, Joseph J, et al. Impact of complications during transfemoral transcatheter aortic valve replacement: how can they be avoided and managed? J Am Heart Assoc. 2019 Sep 17; 8(18): e013801. doi: 10.1161/JAHA.119.013801